Customized Assays Made Easy with scanR TruAI

With the ongoing development of sample preparation protocols, fluorescent markers, and the various cell lines used in screening, it is difficult to provide robust, ready-to-go analysis protocols for a broad range of analysis applications (e.g., apoptosis, autophagy, cell count, cell differentiation, mitotic index, protein expression, and transmigration). As a result, in labs where many different applications or non-standard assays are expected, having the tools to build your own assay is a major advantage.

To achieve this, the Olympus scanR high-content screening (HCS) system uses an assay builder inspired by flow cytometry. Detected objects are displayed in parameter scatter plots where clouds of populations emerge, revealing phenotypes that can be displayed in galleries for visual inspection and gated for statistical quantification (Figures 1 and 2). The analysis parameters can be easily tuned to cover various applications, including kinetic assays.

This same approach based on scatter plots, galleries, and gates is ideal to judge the robustness of deep learning models for image segmentation, a field that is revolutionizing microscopy.

In this webinar, you’ll get an introduction to the scanR HCS system and learn how to:

• Build your own assays with a live demonstration of the workflow
• Use the same tools to validate and judge the performance of neural networks for image analysis

Presenter:

Manoel Veiga Global Application Specialist, Olympus manoel.veiga@olympus.com Manoel Veiga obtained his PhD in physical chemistry at the University Santiago de Compostela, Spain. Following two postdocs at the Universities of Madrid and Münster, he joined PicoQuant. After five years supporting customers around the world in the fluorescence lifetime imaging (FLIM) and time-resolved measurement fields, he joined Olympus Soft Imaging Solutions in 2017, where he works as a Global Application Specialist with a focus on high-content analysis and deep learning.

Customized Assays Made Easy with scanR TruAI With the ongoing development of sample preparation protocols, fluorescent markers, and the various cell lines used in screening, it is difficult to provide robust, ready-to-go analysis protocols for a broad range of analysis applications (e.g., apoptosis, autophagy, cell count, cell differentiation, mitotic index, protein expression, and transmigration). As a result, in labs where many different applications or non-standard assays are expected, having the tools to build your own assay is a major advantage. To achieve this, the Olympus scanR high-content screening (HCS) system uses an assay builder inspired by flow cytometry. Detected objects are displayed in parameter scatter plots where clouds of populations emerge, revealing phenotypes that can be displayed in galleries for visual inspection and gated for statistical quantification (Figures 1 and 2). The analysis parameters can be easily tuned to cover various applications, including kinetic assays. This same approach based on scatter plots, galleries, and gates is ideal to judge the robustness of deep learning models for image segmentation, a field that is revolutionizing microscopy. In this webinar, you’ll get an introduction to the scanR HCS system and learn how to: Build your own assays with a live demonstration of the workflow Use the same tools to validate and judge the performance of neural networks for image analysis Presenter: Manoel Veiga Global Application Specialist, Olympus manoel.veiga@olympus.com Manoel Veiga obtained his PhD in physical chemistry at the University Santiago de Compostela, Spain. Following two postdocs at the Universities of Madrid and Münster, he joined PicoQuant. After five years supporting customers around the world in the fluorescence lifetime imaging (FLIM) and time-resolved measurement fields, he joined Olympus Soft Imaging Solutions in 2017, where he works as a Global Application Specialist with a focus on high-content analysis and deep learning. Preencha o formulário para acessar o webinar EscolherAfghanistanAlbaniaAlgeriaAmerican SamoaAndorraAngolaAnguillaAntarcticaAntigua and BarbudaArgentinaArmeniaArubaAustraliaAustriaAzerbaijanBahamasBahrainBangladeshBarbadosBelarusBelgiumBelizeBeninBermudaBhutanBoliviaBosnia and HerzegovinaBotswanaBrazilBritish Virgin IslandsBrunei DarussalamBulgariaBurkina FasoBurundiCambodiaCameroonCanadaCape VerdeCayman IslandsCentral African RepublicChadChileChinaChristmas IslandCocos IslandsColombiaComorosCongoCongo, Democratic Republic of the Cook IslandsCosta RicaCote d'IvoireCroatiaCubaCyprusCzech RepublicDenmarkDjiboutiDominicaDominican RepublicEcuadorEgyptEl SalvadorEquatorial GuineaEritreaEstoniaEthiopiaFalkland Islands (Malvinas)Faroe IslandsFijiFinlandFranceFrench GuianaFrench PolynesiaGabonGambiaGeorgiaGermanyGhanaGibraltarGreeceGreenlandGrenadaGuadeloupeGuamGuatemalaGuernseyGuineaGuinea-BissauGuyanaHaitiHeard Island and Mcdonald IslandsHoly SeeHondurasHong KongHungaryIcelandIndiaIndonesiaIranIraqIrelandIsle of ManIsraelItalyJamaicaJapanJerseyJordanKazakhstanKenyaKiribatiKorea, Dem. People's Rep. of Korea, Republic of KuwaitKyrgyzstanLao People's Dem. Rep.LatviaLebanonLesothoLiberiaLibyan Arab JamahiriyaLiechtensteinLithuaniaLuxembourgMacaoMacedoniaMadagascarMalawiMalaysiaMaldivesMaliMaltaMarshall IslandsMartiniqueMauritaniaMauritiusMayotteMexicoMicronesia, Federated States ofMoldova, Republic of MonacoMongoliaMontenegroMontserratMoroccoMozambiqueMyanmarNamibiaNauruNepalNetherlandsNetherlands AntillesNew CaledoniaNew ZealandNicaraguaNigerNigeriaNiueNorfolk IslandNorthern Mariana IslandsNorwayOmanPakistanPalauPalestinePanamaPapua New GuineaParaguayPeruPhilippinesPitcairnPolandPortugalPuerto RicoQatarReunionRomaniaRussian FederationRwandaSaint BarthelemySaint HelenaSaint Kitts and NevisSaint LuciaSaint MartinSaint Pierre and MiquelonSaint Vincent and the GrenadinesSamoaSan MarinoSao Tome and PrincipeSaudi ArabiaSenegalSerbiaSeychellesSierra LeoneSingaporeSlovakiaSloveniaSolomon IslandsSomaliaSouth AfricaSpainSri LankaSudanSurinameSvalbard and Jan Mayen IslandsSwazilandSwedenSwitzerlandSyrian Arab RepublicTaiwanTajikistanTanzania, United Republic of ThailandTimor-LesteTogoTokelauTongaTrinidad and TobagoTunisiaTurkeyTurkmenistanTurks and Caicos IslandsTuvaluU.S. Virgin IslandsUSAUgandaUkraineUnited Arab EmiratesUnited KingdomUruguayUzbekistanVanuatuVenezuelaViet NamWallis and Futuna IslandsWestern SaharaYemenZambiaZimbabwe Local * Nome da empresa * Primeiro nome * Sobrenome * E-mail * Cidade CEP * Subscribe to Evident Scientific E-newsletter Por favor, selecione uma divisão investigação acadêmicaBiotecnologiaClínicoEducaçãoDescoberta de medicamentosMedicina regenerativaComponentes OEMOutros Eu concordo com os Termos de Uso e confirmo que li o documento de Política de Privacidade* Enviar If you already have your personal ID enter it here: